RT Journal Article
SR Electronic
A1 Alexander, Lori
T1 Final Results of the ILLUMINATE Trial
JF MD Conference Express
YR 2007
FD SAGE Publications
VO 7
IS 7
SP 14
OP 15
DO 10.1177/155989770700700707
UL http://mdc.sagepub.com/content/7/7/14.abstract
AB The final results of the ILLUMINATE trial comparing the cholesteryl ester transfer protein (CETP) inhibitor torcetrapib plus atorvastatin with atorvastatin alone in patients at high risk for cardiovascular disease showed that the rates of major cardiovascular events and all-cause mortality were higher with the addition of torcetrapib. The study had been prematurely terminated in December 2006 because of a significant excess of deaths and cardiovascular events in the group randomized to torcetrapib plus atorvastatin.